HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $146 to $150.
October 06, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' price target has been raised from $146 to $150 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The news of a price target increase and maintained 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100